Glaxo and Sanofi Are Discussing $620 Million U.K. Vaccine Deal
Laboratory technician handling vaccine research for Covid-19 in France. (Photographer: Adrienne Surprenant/Bloomberg)

Glaxo and Sanofi Are Discussing $620 Million U.K. Vaccine Deal

Bookmark
(Bloomberg) -- GlaxoSmithKline Plc and Sanofi, partners developing a potential coronavirus vaccine, are discussing a 500 million pound ($620 million) deal to supply the U.K. government with the sho...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.